RBM15 and pancreatic adenocarcinoma: This is consistent with previous studies, which found that high expression of RBM15 is significantly associated with tumor progression and poor prognosis in a variety of cancers, including LSCC, COAD, LIHC, and PAAD [26,27,28,29].